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The objective of this study was to develop a bovine viral diarrhoea virus type 2  (BVDV-2) challenge model suitable for evaluation
of efficacy of BVDV vaccines; a model that mimics natural infection and induces clear leucopoenia and viraemia. Clinical,
haematological and virological parameters were evaluated after infection of two age groups of calves (3 months and 9 months)
with two BVDV-2 strains (1362727 and 502643). Calves became pyrexic between 8-9 days post inoculation and exhibited symptoms
such as nasal discharge, mild depression, cough and inappetance. Leukopenia with associated lymphopenia and neutropenia was
evident in all groups with lowest leukocyte and lymphocyte counts reached 8dpi and granulocyte counts between 11 and 16 dpi,
dependent on the strain and age of the calves. A more severe thrombocytopeania was seen in those animals inoculated with strain
1362727. Leukocyte and nasal swab samples were positive by virus isolation, as early as 3 dpi and 2 dpi respectively, independent
of the inocula used. All calves seroconverted with high levels of BVDV-2 neutralising antibodies. BVDV RNA was evident as late as 90
dpi and provides the first evidence of the presence of replicating virus long after recovery from BVDV-2 experimental infection. In
summary, moderate disease can be induced after experimental infection of calves with a low titre (104.8 or 105.0 TCID50) of
virulent BVDV-2, with leucopoenia, thrombocytopoenia, viraemia and virus shedding. These strains represent an attractive model
to assess the protective efficacy of existing and new vaccines against BVDV-2.
  
 Funding statement
 
This work was funded by Pfizer Animal Health (now Zoetis) and DEFRA grant OD0345.
  
 Ethics statements
 (Authors are required to state the ethical considerations of their study in the manuscript, including for caseswhere the study was exempt from ethical approval procedures)
Does the study presented in the manuscript involve human or animal subjects: Yes
Please provide the complete ethics statement for your manuscript. Note that the statement will be directly added to the
manuscript file for peer-review, and should include the following information:
Full name of the ethics committee that approved the study
Consent procedure used for human participants or for animal owners
Any additional considerations of the study in cases where vulnerable populations were involved, for example minors, persons with
disabilities or endangered animal species
As per the Frontiers authors guidelines, you are required to use the following format for statements involving human subjects:
This study was carried out in accordance with the recommendations of [name of guidelines], [name of committee]. The protocol
I re i
ew
was approved by the [name of committee]. All subjects gave written informed consent in accordance with the Declaration of
Helsinki.
For statements involving animal subjects, please use:
This study was carried out in accordance with the recommendations of 'name of guidelines, name of committee'. The protocol
was approved by the 'name of committee'.
If the study was exempt from one or more of the above requirements, please provide a statement with the reason for the
exemption(s).
Ensure that your statement is phrased in a complete way, with clear and concise sentences.
 
The animal study was conducted at Contract Research Unit of the Royal Veterinary College under Home Office Licence number PPL
70/6459 Protocol 19b5 and approved by the Pfizer Animal Health Animal Welfare Committee.
In revi
ew
 1 
Establishment of a bovine viral diarrhoea virus type 2 intranasal challenge 1 
model for assessing vaccine efficacy  2 
 3 
R. Strong a,1, S P. Grahama,2, S.A. La Roccaa, R. Raueb, I. Vangeelb,3, F. Steinbacha   4 
 5 
aVirology Department, Animal and Plant Health Agency, Addlestone, United 6 
Kingdom  7 
bVeterinary Medicine Research & Development, Zoetis, Belgium 8 
1Corresponding author: E-mail: rebecca.strong@apha.gsi.gov.uk 9 
2Current address: The Pirbright Institute, Pirbright, United Kingdom   10 
3Current address: Marcel Buijzestraat 10, 9880 Lotenhulle (Aalter), Belgium  11 
 12 
 13 
Abstract 14 
The objective of this study was to develop a bovine viral diarrhoea virus type 2 15 
(BVDV-2) challenge model suitable for evaluation of efficacy of BVDV vaccines; a 16 
model that mimics natural infection and induces clear leukcopoenia and viraemia. 17 
Clinical, haematological and virological parameters were evaluated after infection of 18 
two age groups of calves (3 months and 9 months) with two BVDV-2 strains 19 
(1362727 and 502643). Calves became pyrexic between 8-9 days post inoculation and 20 
exhibited symptoms such as nasal discharge, mild depression, cough and inappetance. 21 
Leukopenia with associated lymphopenia and neutropenia was evident in all groups 22 
with lowest leukocyte and lymphocyte counts reached 8dpi and granulocyte counts 23 
between 11 and 16 dpi, dependent on the strain and age of the calves. A more severe 24 
thrombocytopeania was seen in those animals inoculated with strain 1362727. 25 
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Leukocyte and nasal swab samples were positive by virus isolation, as early as 3 dpi 26 
and 2 dpi respectively, independent of the inocula used. All calves seroconverted with 27 
high levels of BVDV-2 neutralising antibodies. BVDV RNA was evident as late as 90 28 
dpi and provides the first evidence of the presence of replicating virus long after 29 
recovery from BVDV-2 experimental infection. In summary, moderate disease can be 30 
induced after experimental infection of calves with a low titre (104.8 or 105.0 TCID50) 31 
of virulent BVDV-2, with leukcopoenia, thrombocytopoenia, viraemia and virus 32 
shedding. These strains represent an attractive model to assess the protective efficacy 33 
of existing and new vaccines against BVDV-2. 34 
 35 
 36 
Key words: BVDV-2, experimental infection, pathogenesis, virus persistence, 37 
challenge model 38 
 39 
 40 
Introduction 41 
BVDV is a major pathogen of cattle and also infects a diverse range of ruminants 42 
worldwide (1). It is a member of the family Flaviviridae, genus pestivirus that also 43 
includes border disease virus, classical swine fever virus and atypical pestiviruses. 44 
BVDV exists as two genotypes; BVDV-1 and -2, with a tentative third genotype, 45 
atypical bovine pestiviruses  (2). BVDV-1 and BVDV-2 have been further subdivided 46 
into sub-genotypes based on their genetic characteristics (3). 47 
 48 
BVDV infection in cattle causes a variety of clinical representations, from an 49 
asymptomatic infection to fatal disease (4). Typically, acute infection in postnatal 50 
Formatted: Highlight
Formatted: Highlight
In rev
w
 3 
calves causes a mild transient disease lasting 10-14 days consisting of diarrhoea, 51 
inappetance, respiratory complications and an overall loss of condition. In addition, a 52 
mild pyrexia and transient leukcopenia are apparent for 2 to 3 days with 53 
seroconversion usually before 21 days post-infection (dpi). Infectious virus can be 54 
detected in blood and bodily secretions from calves as early as 4 dpi and up to 15 55 
days. BVDV RNA has been detected by sensitive RT-PCR techniques long after the 56 
acute infection has cleared. This has raised questions about the virus-free status of 57 
animals that have cleared the initial infection and raised an antibody response (5-7). It 58 
has also been reported to reduce milk yields and impact on reproductive performance. 59 
Acute BVDV infection of in-dam heifers can give rise to the birth of persistently-60 
infected (PI) calves, which are able to shed large quantities of virus and thus infect 61 
susceptible herd-mates. The majority of BVD control/eradication programs aim to 62 
identify these animals through the use of appropriate diagnostic assays and remove 63 
them from herds. This in conjunction with vaccination schedules reduces horizontal 64 
transmission to naïve herd-mates and prevents vertical transmission to the foetus. 65 
Therefore, it is necessary to ensure that BVD vaccines afford protection to circulating 66 
strains of BVDV-1 and -2. 67 
 68 
BVDV-2 strains were first associated with a severe haemorrhagic disease with high 69 
mortality in cattle in Canada and USA but strains causing milder disease have been 70 
detected subsequently (8, 9). Over the past ten years, BVDV-2 has been introduced to 71 
Europe through the importation of animals and contaminated products. Recent 72 
outbreaks have been reported in Germany (10), Poland (11), and Spain (12). A range 73 
of pathogenicity of strains has been reported for both BVDV-2 and -1 (13-15). Dose 74 
and virulence of strains, together with the age and immunocompetence of the naïve 75 
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animal have all been implicated as having an effect on the pathogenicity of disease. 76 
Indeed recent studies have found that a more severe clinical disease was observed if 77 
the calf either received a high dose of BVDV-1, or was immunocompromised by the 78 
use of dexamethasone or was only 3 months old (7). 79 
 80 
In this study, we aimed to establish an intranasal BVDV-2 challenge model that 81 
would allow the study of pathogenicity of disease and evaluation of efficacy of 82 
BVDV vaccines without causing severe clinical disease or mortality in naïve animals 83 
(ideally mild to moderate clinical disease). If a potential challenge strain caused a 84 
mild disease in the field, experimentally it may fail to provide clear and measurable 85 
outcomes of disease such as pyrexia, thrombocytopenia and leukopenia. However a 86 
highly virulent field strain may generate these markers of disease but the humane end-87 
point may be reached too soon for the efficacy of a vaccine to be fully evaluated. Thus 88 
Uusing two BVDV-2 strains, the progression of disease was monitored using an 89 
extensive clinical scoring system, virus isolation techniques and by studying 90 
immunological parameters. Evidence of the presence of viral RNA persisting long 91 
after recovery from BVDV-2 infection was additionally evaluated.  92 
 93 
Material and methods 94 
Viruses 95 
The non-cytopathic BVDV-2 strain, 502643, was the first case of BVDV-2 isolated in 96 
the UK from a bull suffering from ill thrift that subsequently died (16). The BVDV-2 97 
strain, 1362727, was isolated from a UK farm in 2006 where the cattle exhibited 98 
severe clinical symptoms with associated death in many cases (17). Virus strains were 99 
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propagated 4 passages on foetal bovine turbinate (fBT) cells. After 5 days incubation, 100 
virus was harvested and titred on fBT cells (16).  101 
 102 
Study design 103 
Experiments were carried out on clinically healthy calves aged 11-13 weeks (Danish 104 
Holstein; male and female calves) or 9 months old (Danish Holstein or Danish Red; 105 
female calves). The calves were confirmed as seronegative for antibodies against 106 
BVDV (HerdChek® BVDV Antibody ELISA, IDEXX Laboratories, Wetherby, 107 
UKBiobest) and tested negative in a BVDV specific RT-PCR (Penrith, APHA). Six 108 
calves 11-13 weeks old and five calves 9 months old were inoculated intranasally 109 
using intranasal applicator (with 105.0 TCID50 of BVDV-2 strain 1362727 (groups 1A 110 
and 1B, respectively). Two groups of five calves (11-13 weeks old and 9 months old) 111 
were inoculated intranasally with 104.8 TCID50 of BVDV-2 strain 502643 (groups 2A 112 
and 2B, respectively). The different inocula were administered in a 2ml volume with 113 
1ml delivered per nostril. The inoculation dose was confirmed through back titration 114 
of the inocula. Animals were monitored once daily from two days prior to inoculation, 115 
until 21 dpi for clinical signs and rectal temperatures were recorded. During these 116 
clinical observations, calves were scored for nasal discharge, ocular 117 
discharge/conjunctivitis, cough, dyspnoea, depression, appetite, diarrhoea and 118 
dehydration each on a scale from 0 to 3 (absent, mild, moderate or severe) according 119 
to the scoring system used previously (7). The 3 month old animals inoculated with 120 
the BVDV-2 strains (group 1A and 2A) were maintained to assess long term infection 121 
whilst the group 1B and 2B animals were euthanized at 21 dpi. One or two animals 122 
from the group 1A and 2A calves were euthanized for post-mortem examinations at 123 
28, 55 and 90 days post inoculation. 124 
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 125 
Ethics Statement 126 
The animal study was conducted at Contract Research Unit of the Royal Veterinary 127 
College under Home Office Licence number PPL 70/6459 Protocol 19b5 and 128 
approved by the Pfizer Animal Health Animal Welfare Committee. 129 
 130 
Virus isolation 131 
Nasal swabs and heparinised blood samples were collected from all animals daily 132 
from 0-14 dpi and on 16 dpi. To isolate virus from leukocytes, blood was centrifuged 133 
at 1500g for 10 min and visible buffy coat material aspirated. Contaminating 134 
erythrocytes were lysed by addition of 10ml of Pharmlyse Buffer (BD Biosciences, 135 
Oxford, UK) and incubation for 10 min at room temperature (RT) before being 136 
washed three times in HBSS (Life Technologies, ThermoFisher Scientific, Paisley, 137 
UK). Virus isolation was carried out on fBT cells as described (7)by Strong et al., 138 
2015. 139 
 140 
Serum neutralisation tests and BVDV antibody ELISA 141 
Blood samples without anti-coagulant were collected on 0 and 21 dpi.  The samples 142 
were left at RT for 2 hours to clot prior to centrifugation at 1500g for 10 minutes. 143 
Samples were tested for BVDV-2 neutralising antibodies by serum neutralisation test, 144 
using a heterologous strain, NADL (18). BVDV specific antibody was detected in 145 
serum samples using a commercial indirect ELISA (HerdChek® BVDV Antibody 146 
ELISA, IDEXX Laboratories, Wetherby, UK) performed according to the 147 
manufacturer’s protocol.  148 
 149 
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Haematology 150 
EDTA treated blood samples for platelet and differential leukocyte counts were 151 
collected daily from -2 to 14 dpi and on 16, 18 and 20 dpi. Platelet and leukocytes 152 
were enumerated by volumetric flow cytometry. In brief, EDTA blood was 153 
centrifuged at 200g for one minute and 5μl of platelet-rich plasma was diluted in 2ml 154 
of CellFIX solution (BD Biosciences). The number of platelets was determined using 155 
a volumetric flow cytometer (MACSQuant Analyzer; Miltenyi Biotec, Bisley, UK). 156 
For total leukocyte counts, EDTA blood was stained with anti-CD45-FITC mAb 157 
clone 1.11.32 (IgG1) (Bio-Rad Antibodies, Oxford, UK) and cell counts were 158 
obtained by gating FITC positive events (19).  159 
 160 
RT-PCR detection of BVDV RNA 161 
EDTA blood samples were taken from group 1A and group 1B calves, that were 162 
remaining on on 28, 42, 55, 70 and 90 dpi. . RNA was extracted from 140µl of blood 163 
using the QIAamp viral RNA extraction kit (Qiagen, Crawley, UK) according to the 164 
manufacturer’s procedure. Viral RNA was detected using a one-step short target real-165 
time RT-PCR assay executed for 50 cyclescycles, which detects both strands of 166 
BVDV RNA (20). Selected RT-PCR positive samples were further tested These 167 
samples were also tested using a two-step negative strand specific RT-PCR that only 168 
detects the presence of the replicative intermediate evident during BVDV genome 169 
replication (7). 170 
 171 
Statistical analysis 172 
Clinical scores were analysed by Kruskal Wallis ranking test. Statistical significance 173 
between groups and between pre- and post-challenge levels was determined using a 174 
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one-way ANOVA test. A Bonferroni adjusted p value of 0.007 was considered 175 
indicative of significance.  176 
  177 
Results 178 
Calves inoculated with either BVDV-2 strain, 1362727 or 502643, exhibited nasal 179 
discharge, coughing, mild depression and inappetence with a peak in mean clinical 180 
score between 8 and 11 dpi (Figure 1A). All calves in all groups developed mild to 181 
moderate clinical disease. Group 1A calves (3 month old calves inoculated with strain 182 
1362727) achieved a higher mean clinical score that was sustained for a longer period 183 
compared to the group 1B calves (9 month old; 1362727). In contrast, group 2B 184 
calves (9 month old calves inoculated with strain 502643) reached a higher mean 185 
clinical score than group 2A calves (3 month old; 502643). Although these differences 186 
were not significant (p=0.305). After inoculation with either BVDV-2 strains, all 187 
animals independent of both age groups of animals exhibited pyrexia (>39.5oC) by 8 188 
dpi with this lasting for 2 days in majority of the animals (Figure 1B).  189 
 190 
Haematology counts were calculated as a percentage of the pre-inoculation baseline. 191 
All groups showed a decrease, albeit not statistically significant compared to pre-192 
inoculation levels (p=0.14), in mean platelets count and reached lowest levels 193 
between 11 and 13 dpi (Figure 2A). Group 1B animals showed the greatest drop in 194 
counts to as low as 38% of the pre-inoculation level at 11 dpi. Platelets count 195 
increased towards baseline levels as the study progressed. Based on the mean total 196 
leukocyte count, all groups of calves exhibited a transient leukopaenia during the 197 
study (Figure 2B). Calves inoculated with strain 1362727 showed the more marked 198 
response compared to 502643 inoculated calves with levels dropping on 8 dpi to as 199 
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low as 45% and 52% of the baseline level for groups 1A and 1B, respectively. There 200 
was a minimal decrease in mean total leukocyte count for group 2B calves due to only 201 
two of the five animals showing any notable decrease in total leukocyte counts.  In all 202 
groups, mean lymphocyte counts decreased to lowest levels at 8 dpi (Figure 2C) with 203 
group 1B animals showing the greatest drop to 47% of pre-inoculation levels, 204 
although this was not significant compared to pre-inoculation levels (p=0.15). 205 
Granulocyte levels initially dropped to the lowest level at 11 dpi in all groups (Figure 206 
2D). Although a further decrease to 27% of the pre-inoculation baseline was reached 207 
for group 1B at 16 dpi. All groups showed monocytosis with highest counts ranging 208 
from 156% - 212% dependent on the inocula and the age of calves (Figure 2E).  209 
 210 
Virus was isolated from nasal swabs and leukocytes isolated from EDTA blood 211 
samples (Table 1; Supplementary Table 1). Virus was isolated from nasal swabs from 212 
group 1A calves inoculated with BVDV-2 strain 1362727 from 2 to 14 dpi and for 213 
group 1B animals from 4 to 10 dpi and 13 to 14 dpi. For the 502643 strain, virus 214 
isolations from nasal swabs were positive 2, 4 to 10 and 16 dpi for animals in group 215 
2A with isolations from all animals on 5 and 9 dpi and from the group 2B animals 216 
from 4 to 10 dpi and 12-13 dpi. Virus was isolated from leukocytes on 3-12, 14 and 217 
16 dpi for the group 1A animals with isolations from all animals on 5, 7 and 8 dpi. For 218 
the group 1B calves, virus was isolated on 5-11 and 13 dpi with all animals testing 219 
positive on 5 dpi. Virus was isolated on 5-9, 11-12 and 16 dpi for the group 2A calves 220 
with isolations from all animals on 5 and 8 dpi. For the group 2B animals, virus was 221 
isolated on 3-14 dpi with all animals being positive on 8 dpi. 222 
 223 
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Blood samples were taken from all groups of animals on 0 and 21 dpi.  For all groups, 224 
calves had seroconverted by 21 dpi (Figure 3A). There was no significant difference 225 
between the mean neutralising antibody titres for any groups. In all groups, BVDV-226 
specific antibody levels increased over the course of the study to levels that were 227 
consistent with seroconversion to the virus (Figure 3B). 228 
 229 
To investigate the presence of replicating virus after the animals had recovered from 230 
an acute infection, group 1B and group 2B animals were maintained up to 90 dpi.. 231 
Individual EDTA blood samples were tested using both the short-target RT-PCR (20) 232 
and RNA positive samples were further tested using the and the negative strand 233 
specific RT-PCR (7). One of the three calves remaining at 90 dpi was RNA positive 234 
when Calves were viral RNA positive up to 90 dpi using the short target PCR which 235 
detects both the viral genome and the replicative intermediate. ThisSamples calf from 236 
group 2B also weretested  positive as late as 70 dpi using the negative strand-specific 237 
RT-PCR which detects only the replicative intermediate (Table 2). Another calf from 238 
group 2B was RNA positive at 55dpi and tested positive using the negative strand-239 
specific RT-PCR at 42 dpi. Of the 3 calves from group 1B tested using the short-240 
target RT-PCR, 3 out of 3 were viral RNA positive at 28 dpi and only 1 out of 3 at 42 241 
dpi. These samples were not tested using the negative-strand specific RT-PCR so it is 242 
not clear if there was actively replicating virus at these time-points. 243 
 244 
Discussion 245 
The purpose of this study was to develop an experimental challenge model for 246 
assessing the efficacy of BVDV vaccines using a BVDV-2 strain that would produce 247 
measurable outcomes, such as leukopeania and viraemia, without severe clinical 248 
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disease. The second area was to investigate the persistence of BVDV-2 since 249 
infections of calves with BVDV-1 resulted in prolonged viraemia and replication (6-250 
7). During the study, mild to moderate clinical symptoms were observed with a peak 251 
in clinical symptoms at around 8 to 10 dpi. However, one animal in group 1A 252 
displayed significant nasal discharge at 6 dpi.  All the group 2A calves received an 253 
anti-inflammatory injection at 11 dpi due to dullness, pyrexia and nasal discharge. 254 
Nevertheless, there was no marked difference in mean clinical score, leukocyte or 255 
platelet counts between this group and the group 2B calves that were infected with the 256 
same BVDV strain at the same dose. The requirement for veterinary intervention may 257 
be attributed to the younger age of the calves in group 2A compared to 2B.All the 258 
group 2A calves and  aA single group 1B calf required veterinary intervention during 259 
the study possibly due to secondary opportunistic bacterial infection that may have 260 
already been present subclinically in the animals before the onset of the study. This 261 
calf exhibited a prolonged pyrexia, inappetance and nasal discharge and lower 262 
leukocyte and platelet counts compared to others group 1B calves. This calf was 263 
treated with Calves were treated with antibiotics and anti-inflammatories  and clinical 264 
signs resolved and leukocyte and platelet counts returned to baseline levels in line 265 
with the other calves.  symptoms resolved within a few days.   266 
 267 
During the study, leukopenia was evident in all groups of calves with associated 268 
lymphopenia and neutropenia which is consistent with another report of experimental 269 
intranasal BVDV-2 infection with both high and low virulent BVDV-2 isolates with 270 
the greater decrease associated with the high virulence strains  (21, 22). Indeed, 271 
inoculation with strain 1362727 promoted a greater decrease in total leukocyte counts 272 
compared to strain 502643 consistent with the more virulent nature of strain 1362727 273 
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compared to strain 502643.   All calves in groups 1A and 1B, inoculated with 274 
1362727, developed thrombocytopenia with levels recovering by three weeks post-275 
inoculation. Little such changes were seen in group 2A and 2B animals, inoculated 276 
with 502653, even though these animals showed clear signs of infection. 277 
Thrombocytopenia has been associated with experimental infection of calves with 278 
either BVDV-1 or -2 isolates (7, 22-25) and in .comparative studies of high and low 279 
virulent strains thrombocytopenia has not developed in calves inoculated with a low 280 
virulent strain (22).  The monocytosis associated with BVDV infection has been 281 
described previously during a study of naturally BVDV-1 infected calves (26). 282 
However, this is in contrast to an experimental intranasal infection with BVDV-2 283 
where a monocytopenia was reported (27).  284 
 285 
Virus was isolated from both nasal swabs and peripheral blood leukocytes from each 286 
animal regardless of the inoculated strain or age of animals, which is consistent with 287 
previous studies of acute BVDV infection (7). Although in this study no naïve ‘in-288 
contact’ animals were included, the presence of virus in the nasal swabs shows the 289 
potential for horizontal transmission. The peak of virus isolation from both nasal swab 290 
and leukocyte samples coincided with the peak of clinical signs and pyrexia observed 291 
in all groups. The presence of BVDV RNA after the clinical signs have resolved and 292 
animals have seroconverted has been reported previously (6, 7, 28-30). The presence 293 
of was detected at 90 dpi and the replicative intermediate as late as 70 dpi which is 294 
consistent with our previous work with experimental BVDV-1 infection ((7)7) and 295 
this . indicates the virus is still replicating long after the calves have recovered from 296 
the initial clinical infection. It is not clear from this study if these calves were capable 297 
of shedding and/or transmitting virus as nasal swabs were not taken at these time 298 
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points and naïve animals were not present. However, previous studies with a BVDV-1 299 
strain demonstrated viral RNA in nasal swabs as late as 80 dpi(7). Although, there 300 
was no transmission of virus to two naïve calves introduced at 50 dpi and maintained 301 
until the end of the study (7). Other experimental infections with BVDV-1 strains 302 
have also been unable to demonstrate the ability of these viral RNA positive, antibody 303 
positive calves to transmit virus to BVDV-naïve herd mates (6). Although studies 304 
have shown that viral RNA positive semen and blood samples collected from animals 305 
that have recovered from the initial infection can infect naïve cattle when injected 306 
intravenously (5, 6). This raises questions about the BVDV-free status of calves that 307 
have recovered from acute infections and mounted an antibody response and whether 308 
they pose a risk to BVDV-naïve animals. This risk may be lower than that posed by PI 309 
calves, which shed large amounts of virus throughout their life. However, these PI 310 
calves are identified and removed from herds and these recovered calves may act as 311 
“virus carriers” thus providing a potential source of infection for naïve herd mates in a 312 
herd deemed to be BVDV free.  Further studies need to be carried out to try to 313 
understand the mechanism by which the virus replicates long after the acute infection 314 
and the impact that this may have on BVDV-naïve herd mates in the field particularly 315 
during BVDV control programs. 316 
The presence of these replicative intermediate at 70 dpi raises questions about the 317 
BVDV-free status of these recovered animals and the potential for recrudescence of 318 
the virus and subsequent virus transmission to herd mates or foetuses alike (6-7). 319 
 320 
The experimental infection reported here for strain 1362727 showed a milder 321 
progression of disease in comparison to the severe clinical disease observed in the 322 
original field infections (13, 31). Previous studies have proposed that other factors 323 
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may have an impact on the progression of the disease in the field such as 324 
environmental factors, immunocompetence, nutritional status and pre-existing 325 
infections. This is supported by our previous study, where a 105.55 TCID50 dose of a 326 
highly pathogenic field strain of BVDV-1 gave rise to a moderate clinical outcome 327 
from which the calves would recover rather than succumb as in the original field 328 
situation. Interestingly, inoculation with strain 502643 originally isolated from a 329 
persistently infected bull with ill-thrift which was present in an asymptomatic herd 330 
gave rise to a measurable clinical outcome.  331 
 332 
 333 
The potential for using either of these viruses as challenge strains for BVDV vaccine 334 
efficacy studies requires that there is measurable clinical disease that does not pose 335 
problems for animal welfare. This was apparent for strain 1362727 and 502643 as 336 
both these strains generated disease with overt clinical symptoms such as pyrexia, 337 
nasal discharge and inappetance in all calves in both age groups. Infectious virus was 338 
isolated from nasal swabs and leukocyte samples from calves inoculated with either 339 
strain independent of the age of the calves. However, a higher number of the calves 340 
inoculated with strain 1362727 achieved a higher than 40% decrease in both 341 
leukocyte (group 1A – 6 out of 6; group 1B – 4 out of 5) and platelet counts (group 342 
1A – 4 out of 6; group 1B – 4 out of 5) compared to those calves inoculated with 343 
strain 502643 in which only 2 out of 5 calves demonstrated this decrease. This would 344 
suggest that strain 1362727 is an attractive candidate for future efficacy studies as it 345 
demonstrated measurable clinical parameters but these were not severe enough to 346 
warrant euthanasia of any of the calves.  347 
 348 
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In conclusion, we present a robust experimental challenge model for BVDV-2 which 349 
induces a range of clinical signs, measurable haematological alterations and viral 350 
loads in peripheral blood and secretions. As such these models will aid in the further 351 
characterisation of BVDV-2 infections and provide a challenge system with which to 352 
assess the protective efficacy of existing and novel BVDV vaccines. It can also be 353 
used for further host-pathogen interaction studies to resolve the nature of the long 354 
term replication of BVDV in host animals. 355 
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 481 
Figure legends 482 
Figure 1. Assessment of the clinical signs and pyrexia induced following experimental 483 
infection of calves with BVDV-2 isolates. Mean clinical scores ± SEM (A) and rectal 484 
temperatures ± SEM (B) following inoculation with BVDV-2 isolates 1362727 485 
(Group 1) and 502643 (Group 2) were assessed in 3 month (Groups 1A and 2A) and 9 486 
month old calves (Groups 1B and 2B).  487 
 488 
Figure 2. Assessment of haematological parameters following experimental infection 489 
of calves with BVDV-2 isolates. Mean values ± SEM for platelets  (A), total 490 
leukocytes (B), lymphocytes (C), granulocytes (D), and monocyte (E) counts are 491 
displayed as a percentage of pre-inoculation baseline counts following inoculation 492 
with BVDV-2 isolates 1362727 (Group 1) and 502643 (Group 2) were assessed in 3 493 
month (Groups 1A and 2A) and 9 month old calves (Groups 1B and 2B).  494 
 495 
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Figure 3. Serological responses following experimental infection of calves with 496 
BVDV-2 isolates. Mean serum neutralising antibody titres (log2 transformed) 497 
measured at 21 dpi (A) and BVDV antibody levels (OD values ± SEM)  (B) are 498 
plotted for calves inoculated with BVDV-2 isolates 1362727 (Group 1) and 502643 499 
(Group 2). 500 
 501 
Table 1. Summary of Virus isolation data 502 
 503 
Group 
Virus 
strain 
Age 
Nasal swabs Leukocytes 
Range of 
detection (days) 
Peak 
detection 
(days) 
Range of 
detection 
(days) 
Peak detection 
(days) 
1A BVDV-2 
(1362727) 
3 months 2-14 - 3-16 5, 7-8 
1B 9 months 4-14 - 5-13 5 
2A BVDV-2 
(502643) 
3 months 2-16 5, 9 5-16 5, 8 
2B 9 months 4-13 - 3-14 8 
 504 
 505 
Table 2. Ct values for short target and negative strand RT-PCR 506 
 507 
Virus PCR Days post inoculation 
  28 43 55 70 90 
BVDV-2 
(502643) 
Short target*  36.76 40.00 36.01 38.19 40.91 
Negative strand**  41.15 38.85 37.61 41.27 No Ct 
 * one-step real-time RT-PCR that detects total viral RNA 508 
 ** two-step real-time RT-PCR that detects only negative strand viral RNA 509 
only 510 
 511 
 512 
 513 
 514 
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